Navigation Links
Cord Blood America Secured $7.5 Million Investment For Series A Preferred Stock
Date:7/7/2009

SANTA MONICA, Calif., July 7 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has entered into a definitive agreement with a health care fund under which Cord Blood America has secured a $7.5 million investment capital commitment, which may be drawn down through the sale of Series A Preferred Stock once a registration statement is filed and declared effective under the Securities Act of 1933.

Proceeds of the investment are anticipated to be used to fund new stem cell initiatives, potential acquisitions, and working capital needs. Matthew Schissler, founder and CEO, said the proceeds, once available and when coupled with internally generated revenues, should be sufficient to fund operations in the foreseeable future.

The Company may drawdown funds from the fund, based on terms and market conditions, through the issuance of Series A Preferred Stock and five-year Warrants exercisable for shares of common stock.

"This long term equity financing will allow for the company to grow and expand in ways we have not seen before, without the constant pressure of discounted debt financing. As stated throughout 2009, our three pillars of planned business success include organic growth, acquisitions and debt reduction. This financing will provide us the capital needed for the first two, without adding debt to the balance sheet."

"To have secured this financing in these difficult economic times is a major signal and endorsement of our business strategies and our management team," Mr. Schissler said.

Ab
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
2. Cord Blood America Continues International Expansion
3. Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
4. Researchers solve bloodcurdling mystery
5. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
6. Cord Blood America Says Debt Reduced $4.194 Million in 2009
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
9. SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal
10. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
11. Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... leadership consulting and culture shaping worldwide, ... firm to lead its global Healthcare and Life Sciences practice. ... Life Sciences, Mitchell will lead a team of more than ... Europe and Asia serving ...
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; ... and Yale University, on March 27 released pre-clinical data ... as an oral presentation by Professor Gil Mor ... 62 nd Annual Scientific Meeting of the Society ... In both in vitro and ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... (NYSE: SGP ) will provide a live ... chairman and chief executive officer, followed,by a question-and-answer ... on Jan. 3, 2008, at approximately 8:45 a.m. ... presentation., Included in Mr. Hassan,s comments will ...
... Fla., Dec. 27 Phlo Corporation,(Pink Sheets: PHLC) ("Phlo") ... completed the initial shipment of its vitality beverage,product, AQISS(TM), ... in the,metropolitan New York City area, including Manhattan, Brooklyn, ... launched in a key account base, some of which ...
... Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China,s,leading ... plans in China. Apart from new plants and ... heavily in training and form strategic alliances,in the ... I. Quality Facilities: New cGMP Pilot Plant ...
Cached Biology Technology:Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base 2Three Steps to Boost Asymchem's Investment in China 2Three Steps to Boost Asymchem's Investment in China 3Three Steps to Boost Asymchem's Investment in China 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Biology Products: